Ticker brief
GILD GILEAD SCIENCES INC
Consumer, Non-cyclical · Biotechnology
last close
$145.68
1 day
-2.1%
14 days
+5.3%
mkt cap
$163.0B
signals 14d
46
authors 14d
30
crowd 14d
+2.3σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 37% rich · 94 pctile own 1y | IV/HV 1.14× (as of 2026-07-31) |
| Skew — 25Δ RR 30d | -0.015 92 pctile own 1y | calls bid vs puts (call skew rich) |
| Net dealer OI (NDOI) | +0.31 normal | 5-session Δ +0.07 (as of 2026-07-06) |
| OI alarm | quiet | last alarm 2026-06-12 (z=2.3) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-15 → 2026-08-28 · now +0.42 (−1 bearish … +1 bullish)
Who spoke30
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @dafster17 | C | -1.15 | 4 | +0.41 |
| @everytimeicash | B | +0.23 | 4 | +0.51 |
| @Asktraders1 | C | · | 4 | +0.36 |
| @StockTraderHub | C | -2.19 | 3 | +0.57 |
| @BiopharmIQ | B | · | 3 | +0.40 |
| @JonkooTrades | B | -1.30 | 2 | +0.57 |
| @TheStreet | C | -0.21 | 2 | +0.25 |
| @Trent_TACap | B | -0.04 | 2 | +0.62 |
| @bioinvestor24 | A | -0.45 | 1 | -0.40 |
| @OptionsHawk | B | +0.24 | 1 | +0.60 |
| @StockPatternPro | C | -0.32 | 1 | +0.50 |
| @KCTrades777 | C | +0.84 | 1 | +0.40 |
| @PortfolioBoss | C | -1.86 | 1 | +0.50 |
| @eToroUS | C | -2.51 | 1 | +0.45 |
| @AsafNaamani | C | -3.38 | 1 | +0.55 |
| @TradeThePool | C | -0.97 | 1 | +0.65 |
| @KunnuInvests | C | -1.52 | 1 | +0.85 |
| @tig88411109 | B | +1.39 | 1 | +0.60 |
| @OracleNYSE | C | -0.08 | 1 | +0.00 |
| @ShakePryzby1 | B | +0.06 | 1 | +0.15 |
| @KeithTradeSmith | C | +0.25 | 1 | +0.55 |
| @OzmosiHealth | C | · | 1 | +0.50 |
| @OHare888 | A | -0.44 | 1 | +0.65 |
| @CNBC | C | +1.09 | 1 | +0.50 |
| @_TP888 | C | -1.12 | 1 | +0.50 |
Recent signals30of 46 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @BiopharmIQ | +0.50 | FDA approved Gilead's once-daily Bixlenvo HIV treatment | — | tweet ↗ |
| 2026-08-28 | @OpenOutcrier | +0.50 | Gilead's once-daily HIV pill received U.S. approval. | — | tweet ↗ |
| 2026-08-28 | @financespotnews | +0.50 | FDA approved Gilead's once-daily HIV treatment Bixlenvo | — | tweet ↗ |
| 2026-08-28 | @Asktraders1 | +0.25 | Gilead now has a new single-tablet HIV treatment based on Biktarvy and lenacapavir. | — | tweet ↗ |
| 2026-08-28 | @Asktraders1 | +0.50 | Gilead won FDA approval for the once-daily Bixlenvo HIV regimen. | — | tweet ↗ |
| 2026-08-28 | @Asktraders1 | +0.35 | Reports Gilead's Q2 HIV sales reached $5.7B, up 12%, alongside Bixlenvo's US approval. | — | tweet ↗ |
| 2026-08-28 | @Asktraders1 | +0.35 | Phase 3 data showed efficacy comparable to Biktarvy; Q2 Biktarvy revenue was $3.8B, up 7%. | — | tweet ↗ |
| 2026-08-27 | @AlertsAndNews | +0.50 | FDA approved Gilead's once-daily Bixlenvo HIV treatment. | -2.1% | tweet ↗ |
| 2026-08-27 | @fwpharma | +0.50 | Reports FDA approval of Gilead's daily HIV treatment pill Bixlenvo. | -2.1% | tweet ↗ |
| 2026-08-27 | @BPharmCatalyst | +0.50 | FDA approved Gilead's Bixlenvo once-daily HIV regimen. | -2.1% | tweet ↗ |
| 2026-08-27 | @_TP888 | +0.50 | Gilead announces FDA approval for Bixlenvo. | -2.1% | tweet ↗ |
| 2026-08-27 | @CNBC | +0.50 | FDA approved Gilead's daily HIV pill for simplified treatment. | -2.1% | tweet ↗ |
| 2026-08-27 | @BiopharmIQ | +0.45 | Details today's GILD FDA catalyst and positive competitive implications for its HIV franchise. | -2.1% | tweet ↗ |
| 2026-08-25 | @OHare888 | +0.65 | Contrasts NVO negatively with disclosed past gains of about 152% in GILD. | -2.1% | tweet ↗ |
| 2026-08-25 | @StockTraderHub | +0.45 | Observes GILD pushing toward a trendline-resistance breakout from an inside bar. | -2.1% | tweet ↗ |
| 2026-08-24 | @StockTraderHub | +0.70 | Maps GILD resistance, support and upside targets after its $145 target was hit. | -0.7% | tweet ↗ |
| 2026-08-24 | @OzmosiHealth | +0.50 | European Commission expanded Trodelvy's first-line breast-cancer indication. | -0.7% | tweet ↗ |
| 2026-08-24 | @BiopharmIQ | +0.25 | Provides a watch list of four imminent FDA decisions and their investor setups. | -0.7% | tweet ↗ |
| 2026-08-23 | @KeithTradeSmith | +0.55 | Argues biotech is an underappreciated bull market supported by momentum, valuations and AI. | -0.3% | tweet ↗ |
| 2026-08-21 | @ShakePryzby1 | +0.15 | Sees a potential biotech leadership cycle and highlights CRSP as a breakout candidate. | -0.3% | tweet ↗ |
| 2026-08-21 | @dafster17 | +0.35 | Discloses holding a sizable PFE LEAPS position and compares its bullish setup with Gilead. | -0.3% | tweet ↗ |
| 2026-08-21 | @dafster17 | +0.65 | Discloses continued ownership of free Gilead runners after selling the top and praises the retest hold. | -0.3% | tweet ↗ |
| 2026-08-20 | @dafster17 | +0.00 | Reports prior-day exits and trims across five stocks. | +1.6% | tweet ↗ |
| 2026-08-20 | @Trent_TACap | +0.60 | Recaps a prior 138 breakout alert that has gained 8%. | +1.6% | tweet ↗ |
| 2026-08-19 | @OracleNYSE | +0.00 | Reports OMC lost GILD as a client account, citing Ad Age. | -1.3% | tweet ↗ |
| 2026-08-19 | @tig88411109 | +0.60 | States Gilead's latest sales exceeded expectations and praises its HIV treatment efficacy. | -1.3% | tweet ↗ |
| 2026-08-19 | @everytimeicash | +0.45 | Celebratory endorsement of gains across GILD, MRK, and COIN, with media needed for detail. | -1.3% | tweet ↗ |
| 2026-08-19 | @KunnuInvests | +0.85 | Explicitly says GILD is going much higher. | -1.3% | tweet ↗ |
| 2026-08-19 | @TradeThePool | +0.65 | Build SKHY and CRM longs; trail and trim the existing GILD long. — Detailed multi-ticker forward plan specifies entries, adds, stops, trims and targets. | -1.3% | tweet ↗ |
| 2026-08-19 | @AsafNaamani | +0.55 | After a 15% gain, watches GILD's all-time high for a breakout and continuation. | -1.3% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.